CDTX News and Press, Cidara Therapeutics Inc. From 05/20/19

Someone’s sitting in the shade today because someone planted a tree a long time ago. - Warren Buffett Writing about antibiotic innovators is a quandary for me because I have to balance between the need for investment profits for investors vs. my social responsibility. It's an inte...

Cidara Therapeutics (NASDAQ: CDTX ): Q1 GAAP EPS of -$0.60 in-line. More news on: Cidara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2019 and provided an update on its corporate a...

Data featured in three oral and five poster presentations reinforce potential of novel antifungal for the treatment and prevention of serious invasive infections Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherap...

CB-012 demonstrates potent antiviral activity against influenza A and B viruses Cidara presenting preclinical results today at ECCMID 2019 Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today annou...

WASHINGTON , April 12, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies will present data from their clinica...

SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at ...

Six poster presentations include new analyses from Phase 2 STRIVE clinical trial of rezafungin Four oral presentations include first scientific presentation of new data highlighting the potential of its Cloudbreak antiviral conjugates (AVCs) for influenza Cidara Therapeutics,...

Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that three rezafungin abstracts have been accepted for presentation at the 45 th Annual European Society for Blood and Marrow Transplantation (EBMT) ...